Drug Channels

OCTOBER 23, 2023

With regulation and policy changes, specifically surrounding the DCSCA, IRA and serialization, the loss of exclusivity wave, adoption of low-WAC products affecting GTN and the rise of alternative distribution models, there has never been a more important time for industry to unite. What can you expect?

Pharmacy 75

Pharmacy Biosimilars Marketing Production 75

Drug Channels

SEPTEMBER 29, 2020

As managing copay programs continues to be significantly more complex, it is imperative to stay on top of current trends, emerging regulations and future legislation. Copyright © 2006-2020 Pembroke Consulting, Inc. It’s time to talk. Offer not valid on workshop-only or non-profit registrations. Drug Channels, or any of its employees.

Pharmacy 40

Pharmacy Compliance Pharmaceuticals Regulations 40

Drug & Device Law

FEBRUARY 20, 2023

2006), app. The court in Wolfe refused to impose a negligence duty on the defendant pharmaceutical company to develop and obtain FDA approval of the plaintiff’s non-FDA-approved alternative. In at least the short term, a popular pain reliever would have to be removed from pharmacies. 2d 839, 851 (N.Y. 2003), aff’d , 810 N.Y.S.2d

FDA 59

FDA FDA Approval Testimonials Vaccine 59

Drug & Device Law

JUNE 2, 2022

Even with some attempt to “stay in our lane,” we can see significant impacts on the legal framework in which a number of medical product manufacturers, to say nothing of distributors, pharmacies, and healthcare providers, operate. This is not a matter of us injecting our personal and political views into areas we do not belong. 472 (2013).

FDA Approval 127

FDA Approval Pharmacy FDA Drugs 127